Entest BioMedical Inc.'s Subsidiary Zander Therapeutics Makes Key Additions to Management Team as the Company Prepares to Move Forward in the $63 Billion Veterinary / Pet Market Niche

Monday, February 6, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

SAN DIEGO, February 6, 2017 /PRNewswire/ --

Zander Prepares to Move Forward

With Development of its Small Molecule Therapies for Treating Animals With Cancer and Autoimmune Disorders Which Include Arthritis 

Entest BioMedical Inc.'s (OTCPINK: ENTB) Zander Therapeutics subsidiary has added Harry

Lander, PhD, MBA as its President and Chief Scientific Officer and Todd S. Caven as its Chief Financial Officer. Thomas Ichim, PhD will assist the company as its Senior Scientific Consultant and Debbie Dorsee will serve as Director of Business Development.

Zander Therapeutics Inc. is focused on the rapidly growing veterinary medicine market niche. In 2016, the U.S. pet market was estimated to be $62.75 billion dollars in size, which is up from $38.5 billion in 2006 and $48.53 billion in 2010. Out of $62.75 billion, $16 billion was spent on veterinary care alone.

Lander has over 25 years of professional scientific, business and financial management experience related to biomedical research. He has a deep knowledge of operations and research administration. . He has extensive relationships with large and small biotechnology and pharmacology expects to leverage for company growth. He has served as Research Chief / Administration for Sidra Medical and Research Center (Doha, Qatar), Assistant Provost for Weill Cornell Medical College (Cornell University) and served as Assistant Dean for Research Administration at Weill Cornell Medical College (Cornell University).

Caven has 30 years of experience in corporate finance, taxation, mergers & acquisitions, corporate valuations and financing activities for various types of transactions. He co-founded Saguaro Capital Partners, an Arizona-based firm that raises growth capital for medical device, pharmacology and technology based companies throughout the western United States. Caven also founded Rock Ridge Enterprises, a Minnesota-based boutique private equity firm that focuses on the acquisition of manufacturing, distribution, construction and business services firms in the upper Midwest. Formerly, Caven served as CFO of Atterro Human Capital Group (formerly Pro Staff), a $500 million privately-held firm in the staffing and recruiting industry. He also held senior-level finance and marketing positions at Nordic Track and the Carlson Companies., both in Minneapolis, Minnesota. He started his career in corporate finance at Amoco Corporation in Chicago, Illinois (now British Petroleum). Caven earned a bachelor's degree in Accounting from the Tippie College of Business at the University of Iowa, and he received an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University.

Dr. Ichim has 20 years of biotechnology experience, including founding Immune Advisors LLC, a biotechnology consulting group focused on accelerating commercialization of companies in the regenerative medicine and immune-oncology space. Dr. Ichim previously served as Chief Scientific Officer and Chief Executive Officer of Medistem Inc. which was acquired by Intrexon Inc. He also co-founded bioRASI (a contract research organization), served as a Vice President of Cellular Therapies at Intrexon Inc. Dr. Ichim has more than 100 peer reviewed publications on cell therapy and immunology and over 100 patents and patent applications.

Debbie Dorsee is the founder and principal executive of The Dorsee Company, a leader in public relations for businesses and individuals both regionally and nationally. She has an integrated focus on community relations, marketing, fundraising / capital raising and business development. Dorsee received the San Diego North Chamber of Commerce's Volunteer of the Year honor and was named one of San Diego Metropolitan Magazine's Metro Movers to Watch.

Zander's Chairman & CEO David Koos noted, "With the addition of these new management team members, Zander is poised to advance its business model rapidly. We have both proprietary intellectual property and licensed intellectual property (from Regen BioPharma Inc.), which are aimed at addressing maladies suffered by our pets through the development of small molecule therapies. The veterinary market is something I'm extremely passionate about, as I have two basset hounds and lost my first basset hound to cancer. I'm excited that Zander can provide therapies that prevent the suffering of our pets."

About Zander Therapeutics Inc.:

Zander Therapeutics is a wholly owned subsidiary of Entest BioMedical Inc. (OTCPink: ENTB), a publicly traded biotechnology company focused on veterinary medicine. The Company seeks to develop small molecule and immune stimulating therapies for veterinary application. Currently, the Company's major interest is in developing small molecule therapies for treating cancer and autoimmune diseases in animals, which include arthritis.

Zander Therapeutics Inc. is the exclusive licensee for veterinary applications of Regen BioPharma Inc. (OTCQB: RGBP) (OTCQB: RGBPP) intellectual property and technology relating to NR2F6. NR2F6 is a molecular switch known as a "orphan nuclear receptor", which controls genes associated with the immune response. Zander Therapeutics is solely focused on veterinary applications.

David Koos serves as Chairman and Chief Executive officer of Regen BioPharma, Inc. (OTCQB: RGBP), Entest BioMedical Inc. (OTCPINK: ENTB) and Zander Therapeutics Inc. (wholly owned by Entest BioMedical Inc.).

Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

CONTACT INFORMATION Zander Therapeutics Inc. and Entest BioMedical Inc. David R. Koos, Ph.D. Chairman & Chief Executive Officer 619-702-1404 Phone 619-330-2328 Fax http://www.zandertherapeutics.com/ info@zandertherapeutics.com

SOURCE Entest BioMedical Inc.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store